TrialJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2025

Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis.

Solange Peters et al.PubMed ↗Publisher ↗

No numbers read from the abstract.